ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 199 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2020. The put-call ratio across all filers is 0.51 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $222,251 | -18.3% | 40,780 | +0.5% | 0.01% | -21.4% |
Q2 2023 | $272,138 | -23.0% | 40,557 | +1.4% | 0.01% | -30.0% |
Q1 2023 | $353,324 | +79.6% | 40,014 | +55.4% | 0.02% | +66.7% |
Q4 2022 | $196,738 | -18.4% | 25,751 | -23.9% | 0.01% | -14.3% |
Q3 2022 | $241,000 | -10.7% | 33,858 | +1.5% | 0.01% | -12.5% |
Q2 2022 | $270,000 | -41.0% | 33,354 | +1.1% | 0.02% | -23.8% |
Q1 2022 | $458,000 | -56.1% | 33,002 | -11.3% | 0.02% | -57.1% |
Q4 2021 | $1,044,000 | -32.0% | 37,197 | -17.6% | 0.05% | -38.0% |
Q3 2021 | $1,535,000 | -16.8% | 45,169 | +0.1% | 0.08% | -16.8% |
Q2 2021 | $1,845,000 | +0.8% | 45,142 | -0.7% | 0.10% | -12.0% |
Q1 2021 | $1,830,000 | -34.1% | 45,447 | -3.2% | 0.11% | -36.8% |
Q4 2020 | $2,775,000 | +21.6% | 46,932 | 0.0% | 0.17% | +8.2% |
Q3 2020 | $2,282,000 | +1.4% | 46,932 | +0.8% | 0.16% | -13.7% |
Q2 2020 | $2,251,000 | +50.2% | 46,537 | -13.7% | 0.18% | +15.8% |
Q1 2020 | $1,499,000 | – | 53,946 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
Triatomic Management LP | 121,166 | $813,024 | 0.83% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |